• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

RenovoRx appoints new SVP of clinical operations

April 11, 2023 By Sean Whooley

RenovoRX RenovoGem drug-delivering pancreatic cancer treatment
A rendering of the RenovoGem platform. [Image courtesy of RenovoRx]
RenovoRx (Nasdaq:RNXT) announced today that it appointed Leesa Gentry as senior vice president of clinical operations.

Los Altos, California-based RenovoRx said Gentry brings with her “valuable leadership experience” to advance the company’s cancer treatment studies. She becomes the fourth addition to the company’s executive management team in the last year. That group includes COO Angela Gill Nelms, CFO James Ahlers and VP and controller Ron Kocak.

Across 29 years of experience in clinical research programs, Gentry spent time in the CRO, pharmaceutical and biotech industries. Past employers include IQVIA (Quintiles), PPD, OmnicareCR and Otsuka. She served as SVP of clinical operations at Evotec. At PPD, Gentry served as global project manager and senior research specialist for clinical systems.

While at Omnicare, Gentry grew the company’s clinical research site network with long-term care, RenovoRx said. At Otsuka, she developed novel methods for improved, streamlined trial implementation in clinical operations, data management and third-party collaboration.

More on new RenovoRx SVP of clinical operations Leesa Gentry

RenovoRx CEO Shaun Bagai called Gentry “an outstanding clinical operations leader.” He added that her “decades of diverse experience” can make an immediate impact on the company’s clinical trials.

“As we continue to build momentum on the heels of our positive, Phase III interim analysis data in pancreatic cancer treatment, we will look to her guidance to enhance our current and future trials,” Bagai said. “We are confident in Leesa’s track record for successful regulatory submissions, late-stage trial preparation, and clinical execution. She will be invaluable in our quest to increase patient lifespans and improve quality of life by developing innovative oncology therapies.”

RenovoRx develops the RenovoGem drug-device combination for treating pancreatic cancer. Recent interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem.

RenovoGem utilizes the RenovoRx proprietary RenovoTAMP therapy platform. It provides targeted intra-arterial delivery of FDA-approved chemotherapy, known as gemcitabine. This treats LAPC following stereotactic body radiation therapy (SBRT). The pressure-mediated delivery technology delivers the therapy locally, across the arterial wall to bathe tumor tissue in chemotherapy.

“RenovoRx is changing the current standard of care for locally advanced pancreatic cancer (LAPC), and I am excited to be a part of the team’s mission,” said Gentry. “With interim data demonstrating clinically significant improvement in overall survival and quality of life for patients undergoing RenovoGem treatment, the team’s progress is impressive. Based on the Company’s pipeline and expected clinical milestones, RenovoRx has tremendous potential for helping patients with difficult-to-treat cancers.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: Personnel Moves, RenovoRx

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS